This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

RotaTeq

Merck & Co., Inc.

Drug Names(s): V260

Description: Rotavirus (RV) is the leading cause of dehydrating gastroenteritis (AGE) in infants worldwide. RotaTeq is a vaccine designed for the prevention of infection by rotavirus. RotaTeq is approved for the prevention of rotavirus gastroenteritis caused by the G1, G2, G3, and G4 serotypes contained in the vaccine in infants age 6 to 32 weeks.

The vaccine contains five reassortants (bovine rotavirus strain WC3 with surface proteins of either human serotype G1, G2, G3, G4, or P1). The bovine strain was chosen because it replicates less prolifically in the human gastrointestinal tract than the simian strain used for the tetravalent rhesus reassortant vaccine. Each of the five reassortants consists of the genetic backbone of the bovine virus with an inserted gene coding for a different human rotavirus surface protein. The inserted genes were selected to represent a broad range of serotypes in order to elicit protection against a wide variety of strains.

Deal Structure: DRI Capital
On an undisclosed date, DRI Capital purchased royalties relating to the sales of RotaTeq for rotavirus. As a result of this transaction, DRI Capital, through its managed private equity funds, owns royalty entitlements for this drug for an undisclosed rate.

Merck and Sanofi Pasteur
In March 2016, Sanofi Pasteur and Merck (MSD) announced their intent to end their joint vaccines operations in Europe. Upon concluding their joint venture, both companies plan to integrate their respective European vaccine businesses into their operations, independently manage their product portfolios and pursue their own distinct growth strategies in Europe.

The joint venture Sanofi Pasteur MSD, owned on a 50/50 basis by Sanofi Pasteur and MSD, was created in 1994 to develop and commercialize vaccines originating from both companies pipelines to improve and promote public health in 19 European countries. Sanofi Pasteur and MSD expect the project to be...See full deal structure in Biomedtracker

Partners: DRI Capital Inc.


RotaTeq News

Pink Sheet RotaTeq recommended


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug